Predictors of Contrast-induced Acute Renal Injury in Patients With Acute Coronary Syndrome (NCT07294911) | Clinical Trial Compass
CompletedNot Applicable
Predictors of Contrast-induced Acute Renal Injury in Patients With Acute Coronary Syndrome
Kazakhstan88 participantsStarted 2024-11-02
Plain-language summary
This observational study aims to identify predictors of contrast-induced acute kidney injury (CI-AKI) in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Clinical, laboratory, and procedural factors will be analyzed to determine their association with the development of CI-AKI. The findings may help improve risk stratification and preventive strategies in this high-risk population.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Age ≥ 18 years
Diagnosis of acute coronary syndrome (STEMI or NSTEMI) confirmed by clinical, ECG, and laboratory findings
Undergoing coronary angiography or percutaneous coronary intervention with intravascular contrast administration
Provided informed consent to participate in the study
Availability of baseline and follow-up serum creatinine values
Exclusion Criteria:
Known chronic kidney disease stage 4 or 5 (eGFR \< 30 mL/min/1.73 m²) or on dialysis
Hemodynamic instability not related to acute coronary syndrome (e.g., septic shock)
Exposure to intravenous contrast within the previous 7 days
Use of nephrotoxic drugs (e.g., aminoglycosides, amphotericin B) within 72 hours prior to contrast exposure
Active infection or inflammatory disease affecting renal function
Pregnancy or breastfeeding
Refusal or inability to provide informed consent
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in serum creatinine at 90 days
Timeframe: 90 days after contrast exposure
2
Incidence of Contrast-Induced Acute Kidney Injury (CI-AKI)
Timeframe: Within 72 hours after contrast exposure